Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Normal glucose levels should be the goal

Type 2 diabetes mellitus (T2DM) is a major public health problem. However, few clinicians screen routinely to detect this problem early or manage hyperglycaemia aggressively if it is found. As even transient normalization of glucose levels in prediabetes reduces the risk of developing T2DM, these practices should change.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Perreault, L. et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379, 2243–2251 (2012).

    Article  CAS  PubMed Central  Google Scholar 

  2. Butler, A. E. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110 (2003).

    Article  CAS  PubMed Central  Google Scholar 

  3. Weyer, C., Bogardus, C., Mott, D. M. & Pratley, R. E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104, 787–794 (1999).

    Article  CAS  PubMed Central  Google Scholar 

  4. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med 346, 393–403 (2002).

    Article  CAS  PubMed Central  Google Scholar 

  5. Colagiuri, S., Cull, C. A., Holman, R. R. & UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diab. Care 25, 1410–1417 (2002).

    Article  Google Scholar 

  6. [No authors listed] Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128, 517–523 (1998).

  7. Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412 (2000).

    Article  CAS  PubMed Central  Google Scholar 

  8. Phillips, L. S. et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetol. 52, 1798–1807 (2009).

    Article  CAS  Google Scholar 

  9. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1203858.

  10. Gong, Q. et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetol. 54, 300–307 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The views expressed are those of the authors and do not represent those of the U.S. Department of Veterans Affairs or Emory University.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lawrence S. Phillips.

Ethics declarations

Competing interests

L. S. Phillips and D. E. Olson have declared associations with the following companies/organizations: Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, Roche and Sanofi (grant/research support), Boehringer Ingelheim and Janssen Pharmaceuticals (scientific advisory boards).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phillips, L., Olson, D. Normal glucose levels should be the goal. Nat Rev Endocrinol 8, 510–512 (2012). https://doi.org/10.1038/nrendo.2012.139

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.139

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing